Skip to main content
Vineet Laboratories Limited logo

Vineet Laboratories Limited — Investor Relations & Filings

Ticker · VINEETLAB ISIN · INE505Y01010 LEI · 98450053FEE2D64C6147 BSE.NS Manufacturing
Open in API
Filings indexed 278 across all filing types
Latest filing 2024-04-16 Regulatory Filings
Country IN India
Listing BSE.NS VINEETLAB

About Vineet Laboratories Limited

http://vineetlabs.co.in/

Vineet Laboratories Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and API intermediates. The company focuses on producing high-quality chemical compounds through advanced research and development, catering to diverse therapeutic segments including anti-retroviral, anti-diabetic, and anti-hypertensive treatments. Its core operations involve the synthesis of complex molecules and fine chemicals, supported by manufacturing facilities that adhere to rigorous quality management systems. Vineet Laboratories provides custom synthesis and contract manufacturing services, positioning itself as a technical partner for global healthcare organizations. The company emphasizes process optimization and cost-effective production to deliver reliable chemical solutions for large-scale pharmaceutical applications.

Recent filings

Filing Released Lang Actions
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2024-04-16 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 100% confidence The document is a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, certifying that no securities were received for dematerialisation/rematerialisation during the quarter ended 31.03.2024. It is a compliance certificate addressed to the Compliance Officer, with no financial statements or detailed report content. The document length is short (1183 characters) and it serves as an attestation or confirmation letter rather than a financial report or announcement. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS).
2024-04-12 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges informing about the closure of the trading window pursuant to SEBI regulations ahead of the announcement of the company's audited financial results for the fiscal year ending March 31, 2024. It mentions the upcoming board meeting date for declaration of the audited financial results will be intimated later. The document does not contain any financial data or the actual financial results but is an announcement related to compliance and trading restrictions before the financial results are published. The document length is short (1793 characters) and it serves as a notification rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance communication.
2024-03-29 English
Copy of Newspaper Publication
Regulatory Filings
2024-02-14 English
Outcome of Board Meeting
Regulatory Filings
2024-02-12 English
Financial Result Updates
Regulatory Filings
2024-02-12 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.